Moderna cancer vaccine with Merck’s Keytruda delays return of deadly skin cancer
The findings suggest that adding a personalized cancer vaccine based on mRNA technology to Keytruda, which improves the immune response, could prolong the time patients have without recurrence or death, said Dr. Jeffrey Weber of the NYU…